Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lipoprotein apheresi"'
Autor:
Tiziana Sampietro, Marcello Arca, Paolo Calabrò, Olga Kalmykova, Livia Pisciotta, Stefano Bertolini, Gabriella Iannuzzo, Francesco Sbrana, Fabio Nota, Antonio Gallo, Carlo Sabbà, Patrizia Suppressa, Arturo Cesaro, Giuliana Fortunato, Randa Bittar, Arturo Puja, Marco Bucci, Katia Bonomo, Angelo B. Cefalù, Samir Saheb, Maurizio Averna, Tiziana Montalcini, Alessio Buonaiuto, Sergio D'Addato, Alain Carrié, Chiara Pavanello, Sophie Béliard, Alessia Di Costanzo, S. Palmisano, Eric Bruckert, Giovanni Battista Vigna, Antonina Giammanco, Laura Calabresi, Fabio Fimiani, Laura D'Erasmo
Publikováno v:
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, 2021, 16 (1), pp.381. ⟨10.1186/s13023-021-01999-8⟩
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-12 (2021)
Orphanet Journal of Rare Diseases, 2021, 16 (1), pp.381. ⟨10.1186/s13023-021-01999-8⟩
Orphanet Journal of Rare Diseases, Vol 16, Iss 1, Pp 1-12 (2021)
Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91309aad8e5cd225dae970068787de6
https://doi.org/10.1186/s13023-021-01999-8
https://doi.org/10.1186/s13023-021-01999-8
Autor:
M. Tripaldella, Raffaele Carluccio, Gabriella Iannuzzo, Nicoletta Vitelli, Vania Mallardo, Anna Tramontano, Mena Morgillo, Francesco Giallauria, Matteo Nicola Dario Di Minno, Emilio Aliberti, Ilenia Calcaterra, Marco Gentile, Arcangelo Iannuzzi
Publikováno v:
Biomedicines, Vol 9, Iss 838, p 838 (2021)
Biomedicines
Biomedicines
A number of epidemiologic studies have demonstrated a strong association between increasing lipoprotein a [Lp(a)] and cardiovascular disease. This correlation was demonstrated independent of other known cardiovascular (CV) risk factors. Screening for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d80ee2a2360fae85975a3be051de08ce
http://hdl.handle.net/11588/855600
http://hdl.handle.net/11588/855600
Autor:
S. Di Giacomo, Maurizio Averna, Dirk J. Blom, Daniel J. Rader, G.B. Vigna, H. dT. Theron, Daniel Gaudet, Claudia Stefanutti, Emma A. Meagher, LeAnne Bloedon, Bruce S. Sachais, Adrian David Marais, Prediman K. Shah, Marina Cuchel, A.M.E. du Plessis, Robert A. Hegele, J. Balser, Cesare R. Sirtori
Publikováno v:
Atherosclerosis. 240(2):408-414
ObjectiveLomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a685f25f9cd01e65aa1f61e9d129714
A retrospective study--the Italian Multicenter Study on Low-density Lipoprotein Apheresis (IMS-LDLa)--was carried out, which involved 19 centers for LDLa in Italy, distributed all over the country--in the north, center, south, and the major islands.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b895d150bafddf21ef812da33d2ddec
https://hdl.handle.net/11368/2503956
https://hdl.handle.net/11368/2503956